Top

Published in:

Open Access 01-05-2012 | Original Article

The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study

Authors: T. Y. Tai, K. S. Tsai, S. T. Tu, J. S. Wu, C. I. Chang, C. L. Chen, N. S. Shaw, H. Y. Peng, S. Y. Wang, C. H. Wu

Published in: Osteoporosis International | Issue 5/2012

Abstract

Summary

The treatment of 300-mg/day isoflavones (aglycone equivalents) (172.5 mg genistein + 127.5 mg daidzein) for 2 years failed to prevent lumbar spine and total proximal femur bone mineral density (BMD) from declining as compared with the placebo group in a randomized, double-blind, two-arm designed study enrolling 431 postmenopausal women 45–65 years old.

Introduction

This study evaluated the effects of soy isoflavones on bone metabolism in postmenopausal women.

Methods

Four hundred and thirty-one women, aged 45–65 years, orally consumed 300-mg/day isoflavones (aglycone equivalents) or a placebo for 2 years in a parallel group, randomized, double-blind, two-arm study. Each participant also ingested 600 mg of calcium and 125 IU of vitamin D₃ per day. The BMD of the lumbar spine and total proximal femur were measured using dual-energy X-ray absorptiometry at baseline and every half-year thereafter. Serum bone-specific alkaline phosphatase, urinary N-telopeptide of type 1 collagen/creatinine, and other safety assessments were examined regularly.

Results

Two hundred out of 217 subjects in the isoflavone group and 199 out of 214 cases in placebo group completed the treatment. Serum concentrations of isoflavone metabolites, genistein and daidzein, of the intervention group were remarkably elevated following intake of isoflavones (p < 0.001). However, differences in the mean percentage changes of BMD throughout the treatment period were not statistically significant (lumbar spine, p = 0.42; total femur, p = 0.39) between the isoflavone and placebo groups, according to the generalized estimating equation (GEE) method. A significant time trend of bone loss was observed at both sites as assessed by the GEE method following repeated measurement of BMD (p < 0.001). Differences in bone marker levels were not significant between the two treatment groups.

Conclusion

Treatment with 300-mg/day isoflavones (aglycone equivalents) failed to prevent a decline in BMD in the lumbar spine or total femur compared with the placebo group.

Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2:7PubMedCrossRef

Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285:2891–2897PubMedCrossRef

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712PubMedCrossRef

Miksicek RJ (1994) Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 49:153–160PubMedCrossRef

Zava DT, Duwe G (1997) Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 27:31–40PubMedCrossRef

Brandi ML (1997) Natural and synthetic isoflavones in the prevention and treatment of chronic diseases. Calcif Tissue Int 61(Suppl 1):S5–S8PubMedCrossRef

Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr (1998) Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68:1375S–1379SPubMed

Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T (2000) Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 72:844–852PubMed

10.

Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D’Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F (2002) Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 17:1904–1912PubMedCrossRef

11.

Chen YM, Ho SC, Lam SS, Ho SS, Woo JL (2003) Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 88:4740–4747PubMedCrossRef

12.

Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ (2003) The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol (Oxf) 58:704–709CrossRef

13.

Kotsopoulos D, Dalais FS, Liang YL, McGrath BP, Teede HJ (2000) The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric 3:161–167PubMedCrossRef

14.

Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ (2000) Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 18:1068–1074PubMed

15.

Nikander E, Kilkkinen A, Metsa-Heikkila M, Adlercreutz H, Pietinen P, Tiitinen A, Ylikorkala O (2003) A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 101:1213–1220PubMedCrossRef

16.

Franke AA, Custer LJ, Wang W, Shi CY (1998) HPLC analysis of isoflavonoids and other phenolic agents from foods and from human fluids. Proc Soc Exp Biol Med 217:263–273PubMed

17.

Booth M (2000) Assessment of physical activity: an international perspective. Res Q Exerc Sport 71:S114–S120PubMed

18.

Liu YM (2004) Validation of the Taiwan International Physical Activity Questionnaire-Short Form (Doctoral Dissertation in Chinese), in Institute of Nursing, National Taiwan University, Taipei, Taiwan

19.

Hsu HF, Chang CL, Chu YH (2000) Flavonoids amounts and antioxidant analysis in several vegetables. Taiwanese J Agric Chem Food Sci 38:377–387

20.

Liu SW (2003) Validation of a food frequency questionnaire estimating flavonoids, isoflavones and carotenoids intake among elderly population. (Master Dissertation in Chinese). In Institute of Nutritional Science, Fu-Jen Catholic University, Taipei, Taiwan

21.

US Food and Drug Administration, Center for Drug Evaluation and Research (1993) Coding symbols for thesaurus of adverse reaction terms (COSTART), 4th edn. US Food and Drug Administration, Rockville

22.

Xin Y, Yang HY (2006) Influence of daidzein tablets on climacteric syndrome and bone mineral density of women. Chin J Osteoporos 12:149–151

23.

Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, Frisina N, Lubrano C, Bonaiuto M, D’Anna R, Cannata ML, Corrado F, Adamo EB, Wilson S, Squadrito F (2007) Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 146:839–847PubMed

24.

Taku K, Melby MK, Kurzer MS, Mizuno S, Watanabe S, Ishimi Y (2010) Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. Bone 47:413–423PubMedCrossRef

25.

Taku K, Melby MK, Takebayashi J, Mizuno S, Ishimi Y, Omori T, Watanabe S (2010) Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr 19:33–42PubMed

26.

Gallagher JC, Satpathy R, Rafferty K, Haynatzka V (2004) The effect of soy protein isolate on bone metabolism. Menopause 11:290–298PubMedCrossRef

27.

Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT (2004) Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 292:65–74PubMedCrossRef

28.

Arjmandi BH, Lucas EA, Khalil DA, Devareddy L, Smith BJ, McDonald J, Arquitt AB, Payton ME, Mason C (2005) One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J 4:8PubMedCrossRef

29.

Wu J, Oka J, Tabata I, Higuchi M, Toda T, Fuku N, Ezaki J, Sugiyama F, Uchiyama S, Yamada K, Ishimi Y (2006) Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial. J Bone Miner Res 21:780–789PubMedCrossRef

30.

Evans EM, Racette SB, Van Pelt RE, Peterson LR, Villareal DT (2007) Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women. Menopause 14:481–488PubMedCrossRef

31.

Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F (2008) Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study. Am J Clin Nutr 87:761–770PubMed

32.

Kenny AM, Mangano KM, Abourizk RH, Bruno RS, Anamani DE, Kleppinger A, Walsh SJ, Prestwood KM, Kerstetter JE (2009) Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. Am J Clin Nutr 90:234–242PubMedCrossRef

33.

Vupadhyayula PM, Gallagher JC, Templin T, Logsdon SM, Smith LM (2009) Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal women—a 2-year randomized, double-blind, placebo-controlled trial. Menopause 16:320–328PubMedCrossRef

34.

Alekel DL, Van Loan MD, Koehler KJ, Hanson LN, Stewart JW, Hanson KB, Kurzer MS, Peterson CT (2010) The soy isoflavones for reducing bone loss (SIRBL) study: a 3-y randomized controlled trial in postmenopausal women. Am J Clin Nutr 91:218–230PubMedCrossRef

35.

Weaver CM, Cheong JM (2005) Soy isoflavones and bone health: the relationship is still unclear. J Nutr 135:1243–1247PubMed

36.

Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T (2004) Soymilk or progesterone for prevention of bone loss—a 2 year randomized, placebo-controlled trial. Eur J Nutr 43:246–257PubMedCrossRef

37.

Newton KM, LaCroix AZ, Levy L, Li SS, Qu P, Potter JD, Lampe JW (2006) Soy protein and bone mineral density in older men and women: a randomized trial. Maturitas 55:270–277PubMedCrossRef

38.

Whitten PL, Patisaul HB (2001) Cross-species and interassay comparisons of phytoestrogen action. Environ Health Perspect 109(Suppl 1):5–20PubMed

39.

Tsai KS, Hsu SH, Cheng JP, Yang RS (1997) Vitamin D stores of urban women in Taipei: effect on bone density and bone turnover, and seasonal variation. Bone 20:371–374PubMedCrossRef

40.

Lee MS, Li HL, Hung TH, Chang HY, Yang FL, Wahlqvist ML (2008) Vitamin D intake and its food sources in Taiwanese. Asia Pac J Clin Nutr 17:397–407PubMed

41.

Zhang X, Shu XO, Li H, Yang G, Li Q, Gao YT, Zheng W (2005) Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 165:1890–1895PubMedCrossRef

Title: The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study
Authors: T. Y. Tai
K. S. Tsai
S. T. Tu
J. S. Wu
C. I. Chang
C. L. Chen
N. S. Shaw
H. Y. Peng
S. Y. Wang
C. H. Wu
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 5/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1750-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

The cost of fall related presentations to the ED: A prospective, in-person, patient-tracking analysis of health resource utilization

Response to “Effects of Vitamin K intake on gamma-carboxylated proteins, bone fractures, and vascular calcifications”

Is vascular calcification associated with bone mineral density and osteoporotic fractures in ambulatory, elderly women?

A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving

Effects of vitamin K intake on gamma-carboxylated proteins, bone fractures, and vascular calcifications

Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty